Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 September 2021 | Story Michelle Nöthling | Photo Supplied
Peet Jacobs.

Peet Jacobs is no stranger to the Deaf community in and around the UFS and Bloemfontein. He has been working at the University of the Free State (UFS) for the past six years, and he is still amazed at the amount of support our institution provides to Deaf students in particular, and to South African Sign Language (SASL) in general. “They provide excellent interpreting services,” Peet says, “not only in face-to-face classes, but also on different online platforms, as well as interpreting pre-recorded lectures and videos.” And as a SASL interpreter, Peet is an integral part of this service. 

But signing is not merely a day job for Peet. He carries his skill into the community in his spare time, where he assists as an interpreter at hospitals, doctors’ rooms, and psychiatrists’ offices – to name but a few. What gives Peet the deepest satisfaction, however, is when he can combine his love of Sign Language with his love of the Bible and his God. It was actually Peet’s devotion to his religion that inspired him to learn Sign Language in order to enable him to carry the Word of God into the Deaf community. Peet now also presents Bible courses in SASL and assists a non-profit organisation to produce SASL Bible-based publications, which are translated and recorded in video format. 

Peet aspires to become an authority on SASL subject-specific vocabulary related to subject in higher education. “Sign Language is a language in its own right,” Peet points out. “The uniqueness of Deaf culture and the variety of dialects within SASL give the language diversity and colour.” Peet goes on to emphasise how important it is that SASL is recognised as an official language in our country. “This recognition will give dignity to a group of people who have been marginalised in South Africa. This will also pave the way to providing more inclusivity and service to the Deaf community.”

Until then, Peet will continue to serve the best way he knows how: through signing.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept